Hello everyone and welcome to all our new members,
This company could be on the cusp of something monumental as their lead product is a disruptive “world’s first” in this med-tech space.
Sharps Technology, Inc. (NASDAQ: STSS)
The company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features.
These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use.
STSS has several potential near-term catalysts
No. 1 – Another Low Float NASDAQ That Could Provide Significant Potential with Explosive Volatility
No. 2 – 2023 Could Be a Huge Year for Sharps as Their New Product Launch Nears
No. 3 – With Manufacturing Ramping Up, Revenue Should Be Just Around the Corner
No. 4 – New Distribution Agreement Signed
More on those in a second…
Injections Should Not Cause Infections
With healthcare workers delivering more than 16Bn injections a year worldwide, the risk of accidental needlestick injuries and exposure to dangerous bloodborne pathogens is real and urgent.
In fact, the World Health Organization (WHO) has named needlestick injuries “one of the greatest risks faced by the frontline healthcare worker.”
The U.S. Centers for Disease Control and Prevention (CDC) even made eliminating them a national priority, pushing for the healthcare industry to fully adopt safety syringes by 2020—a goal which has not been reached.
Why not? One explanation: Virtually every safety syringe introduced so far has required the user to activate hinges, slides, or springs to engage their safety mechanisms.
Lack of standardized design, their complexity, and practice changes are barriers to compliance, and may even be contributing to the problem.
Nearly 40% of needle injuries involve a safety needle—the vast majority because users did not activate the safety features. The other 60% involve traditional syringes with no safety features at all.
Needlesticks disrupt the lives of at least half a million healthcare personnel each and every year, often with devastating results, including infections, psychological trauma, destroyed careers, and financial ruin.
Sharps Technology offers a solution to this global healthcare crisis.
Sharps Provensa smart safety syringes are the first of their kind designed to eliminate two million potentially infectious accidental needlestick injuries, as well as $Bn’s in medicine wasted with today’s inefficient syringes.
Sharps Provensa™ syringes are addressing the important needs of the global healthcare market:
- Provides automatic protection from accidental needlestick injection for clinicians and all who come in contact with contaminated needles.
- Prevents improper reuse of both needle and syringe by automatically locking the plunger and shielded needle following injection.
- Ultra Low-Waste™ dramatically reduces the number of costly medications discarded with inefficient injections.
For the first time ever, needlesticks can be completely avoided, easing the financial burden on the healthcare system and giving clinical staff and the general public total protection and true peace of mind.
Sharps Provensa™ is the company’s premier line of smart safety syringes that offer solutions to global healthcare crises.
Their Ultra-Low Waste™ syringes offer a solution to minimize vaccine waste while offering reliable needlestick protection.
The Sharps Provensa™ needle tip goes through the skin sharp, delivering the medicine or vaccine, and comes out of the body shielded, protecting the healthcare worker and the public.
Sharps Technology syringes are patented and comply with US regulatory and WHO guidelines.
Their safety syringes are currently being produced at the company’s ISO certified, FDA-cleared facility for medical device production with CE mark approval.
Key company details available here.
And as mentioned previously, STSS has multiple potential near-term catalysts.
No. 1 STSS Potential Catalyst – Another Low Floater Could Provide Significant Potential For Explosive Volatility
According to Yahoo Finance STSS has approximately 5.6M shares in the public float.
Why is that important? It’s important on one crucial level. Volatility!
Could positive company news early in 2023 provide a near term spark?
No. 2 STSS Potential Catalyst – 2023 Could Be A HUGE Year for Sharps (New Product Launch Nears)
Sharps Technology Inc. to Introduce New Specialized Prefillable Syringe Systems in 2023.
High-Value specialized prefillable syringe systems to accelerate revenue growth in 2023 and beyond.
Company to launch next generation specialty polymer-based syringe products for the healthcare market.
NEW YORK, Jan. 10, 2023 (GLOBE NEWSWIRE) — Sharps Technology, Inc. (the “Company”, “Sharps”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces the advancement of the Company’s specialized prefillable syringe (“PFS”) system product line, which will be manufactured in collaboration with Nephron Pharmaceuticals at the Inject EZ facility in West Columbia, South Carolina.
Braden Miller, Sharps Director of Product Management, commented, “Sharps has developed an alternative high-quality solution to glass syringes through the use of inert polymers such as Cyclic Olefin Polymer (COP) and Cyclic Olefin Copolymer (COC), which offers a high-quality solution compared to traditional glass syringe systems. These polymer syringes have many of the same characteristics as current pharmaceutical glass designs to support long term drug stability and increase shelf life for customers in the pharmaceutical segment. Polymer syringes can also be made into custom configurations, which can eliminate breakage, minimize dead space, reduce contamination, and support the development of custom devices including autoinjectors. The ability to produce these innovative products using advanced manufacturing techniques creates additional advantages in the areas of quality, performance and safety when compared to similar glass syringe products. We look forward to introducing this line of next generation products to the market.”
Sharps’ specialized product pipeline and market strategy will include a broad range of sizes, silicon free systems that address contamination issues for the broader healthcare market, dual chamber systems that improve drug shelf life while reducing unnecessary packaging, and customized solutions for systems that serve the growing autoinjector segment.
Sharps announced a manufacturing and research partnership with Nephron Pharmaceuticals in November 2022 that will support the manufacturing of the Company’s new innovative prefillable syringe systems, which will begin in the third quarter of 2023 in South Carolina. Initial demand will be supported by manufacturing capacity of 20+Mn units, with additional capacities that can be scaled by 2025 with an additional 100Mn units annually. Products will be manufactured utilizing state-of-the-art Injection molding technologies with highly automated assembly lines. The products will be sterilized using an ecofriendly clean sterilization option easily adaptable for the pharmaceutical market. Sharps’ PFS systems will utilize ISO Standard Nest and Tubs that will be compatible with existing fill-finish technologies to provide a drop-in solution for the industry.
Robert Hayes, Sharps Chief Executive Officer, commented: “Following years of research and development, Sharps is now in a position to commercialize and support the future of specialty syringe drug filling technology. The opp. to advance our product and manufacturing strategy to include high value prefillable syringe products will significantly accelerate our revenue growth for 2023 and beyond. The launch of these products could not come at a better time to support a market that is in demand for products produced in the USA that provide specialized solutions for customers that need optionality for their drug filling operations. We look forward to providing updates as we commence manufacturing in South Carolina and introduce our new products to the market.”
No. 3 STSS Potential Catalyst – With Manufacturing Ramping Up, Revenue Should Be Getting Even Closer
Sharps Technology Begins Manufacturing at its Hungary Facility for the Company’s Innovative Syringe Products.
Company now transitions from a pre-revenue research & development start-up to a revenue generating manufacturing company.
Shipments to commence by the end of the year to support the recently announced distribution and sales agreement with Nephron Pharmaceuticals and its European customers.
NEW YORK, Dec. 20, 2022 (GLOBE NEWSWIRE) — Sharps Technology, Inc. (the “Company”, “Sharps”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces they have commenced manufacturing of their much-needed ultra-low waste smart safety syringe products in their European operation in Hungary. The plant has been producing products and will begin shipments to support the distribution and sales agreement with Nephron Pharmaceuticals by the end of the year, and customer agreements in Europe in early 2023. The production of these specialty syringe products will ramp up over the next several months to increase supply.
Robert Hayes, Sharps Technology CEO commented: “This is a transformative point for our company as we move from a pre-revenue research & development start-up to a true manufacturing company that should generate revenue in the first half of 2023. Today’s healthcare providers are responsible for managing their supply chains and driving down their total cost of ownership (TCO) for medical treatments. Sharps Technology will be able to offer products that can directly support those programs. At Sharps Technology, we feel that by using better drug delivery technology, we can help create additional medical treatments at no additional cost for patients that need them.”
“We look forward to a bright future at Sharps Technology,” concluded Mr. Hayes. “The recently signed distribution agreement with Nephron Pharmaceuticals accelerates the sales plan for our innovative syringe products that are currently being produced in the Sharps plant in Hungary. The ability to pull forward our sales plan for customers in the US will create a unique opp. for early revenue at Sharps. We expect to have our first products available for sale in the US by the end of January 2023, with additional products to be added to the distribution network by mid-year of 2023.”
No. 4 STSS Potential Catalyst – New Distro Agreement Signed, 2023 Continues To Look Brighter And Brighter
Sharps Technology and Nephron Pharmaceuticals Sign Distribution Agreement for its Innovative Syringe Products.
Company anticipates products to be available in the first quarter of 2023 with initial revenue from this agreement expected in the first half of the year.
Strengthens the collaboration between Sharps and Nephron to advance the previously announced Inject-EZ startup in South Carolina in early 2023.
NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) — Sharps Technology, Inc. (the “Company”, “Sharps”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, is pleased to announce the signing of a distribution agreement with partner Nephron Pharmaceuticals. This is a strategic first step in building the larger partnership between the two companies and is in support of their recently announced collaboration.
“This distribution agreement opens so many possibilities for Sharps Technology and Nephron Pharmaceuticals,” commented Robert Hayes, Sharps Technology CEO. “The timing is perfect in that we are expanding our ability to supply innovative drug delivery systems at a point when the market is in demand for them. Through this distribution plan, Sharps Technology will be able to deliver increased capacity, driving growth for one of the high value product segments of our business.”
We will be back with more on STSS soon,
The Traders News Team